• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: efgartigimod alfa-fcab
Trade Name: Vyvgart
Date Designated: 09/20/2017
Orphan Designation: Treatment of myasthenia gravis
Orphan Designation Status: Designated/Approved
argenx BV
Industriepark Zwijnaarde 7
Zwijnaarde 9052
Belgium

The sponsor address listed is the last reported by the sponsor to OOPD.

Marketing approved:

1 Generic Name: efgartigimod alfa-fcab
Trade Name: Vyvgart
Marketing Approval Date: 12/17/2021
Approved Labeled Indication: treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
Exclusivity End Date: 12/17/2028 
Exclusivity Protected Indication* :  treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive
2 Generic Name: efgartigimod alfa-fcab
Trade Name: Vyvgart
Marketing Approval Date: 05/08/2026
Approved Labeled Indication: treatment of adult patients with generalized myasthenia gravis (gMG)
Exclusivity End Date: TBD  

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-